Paper
0
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Authors
María Casanova,Berta Caballol
Valle García-Sánchez,Francisco Mesonero,Cristina Célix,Patricia Suárez-Álvarez,R Iglesias,María Martín‐Rodríguez,Carla Gargallo-Puyuelo,Pilar Varela-Trastoy,Guillermo Bastida,Marta Carrillo‐Palau,Andrea Núñez‐Ortiz,Patricia Piscina,Daniel Ceballos,Daniel Hervías-Cruz,Fernando Bermejo,David Busquets,Manuel Cabacino,Patricia Camo-Monterde,Ignacio Marín-Jiménez,M. Muñoz,Luisa Peña,Eva Sierra-Moros,Jesús Barrio,Luis Bujanda,Fiorella Cañete,Fernando Gomollón,Noemí Manceñido,Iago Rodríguez‐Lago,María Rodríguez-Grau,Beatriz Sicilia,Sandra Torra-Alsina,Laura Arranz-Hernández,Daniel Carpio,Mariana García-Sepulcre,Carlos Taxonera,José Huguet,Lucía Márquez,María López-Serrano,Ángel Ponferrada-Díaz,María Martín‐Arranz,Javier Gisbert,Rocío Ferreiro-Iglesias,Ruth Francisco,Marta Carrillo-Palau,Roser Muñoz-Pérez,Benito Velayos,Eduard Brunet-Mas,Carlos González‐Muñoza
+48 authors
,María ChaparroJournal
Published
Jun 1, 2024
Show more
Save
Tip0
TipSave
Abstract
The efficacy of ustekinumab and vedolizumab for treating complex perianal fistula in Crohn's disease has been barely studied. We aimed to assess treatment persistence, clinical remission, and safety of these drugs in this context.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.